Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived CMV-specific T cells to prevent CMV reactivation after allogeneic stem cell transplantation
IRCT20140818018842N30Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CMV-specific T cells (University Hospital, Ghent) in cytomegalovirus disease (CMV) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Grades 3-5 infusion-related adverse events and CMV reactivation. Started Feb 2023; status: completed.
02
Drugs
CMV-specific T cells (University Hospital, Ghent)
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on IRCT20140818018842N30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N30.